Nature retracts landmark study on beta-amyloid and Alzheimer's after eighteen years

Nature has formally retracted the study published on March 6, 2006, which claimed to have identified a key mechanism in the onset of Alzheimer’s disease linked to the beta-amyloid protein. For eighteen years, international research relied on those results, considered among the pillars of the hypothesis linking the accumulation of this protein to the development of dementia.

The first to raise doubts was neurologist Matthew Schrag, whose observations opened a verification process that lasted years. In 2022 the journal Science had published photographic evidence calling into question the authenticity of the images contained in the original study, material on which the article’s conclusions were based. Only now, after a further investigation, has Nature’s editorial team decided to proceed with the retraction.

In the official explanation the journal wrote: “we therefore believe that the most appropriate course of action is to retract the article.” The statement closes a case that has spanned nearly two decades of publications, funding and research built, in part, on that work.

On the limitations of the original study, the available material allows us to say the following: the 2006 conclusions were based on experimental images, now judged to have been manipulated, and were formulated as an association between the accumulation of the beta-amyloid protein and the onset of Alzheimer’s — not as a demonstration of direct causality in humans. The sources gathered do not specify the sample size used nor the stage of the experimentation, and do not report any conflicts of interest declared by the authors at the time of publication: these details are not available in the material consulted for this piece.

The case draws attention back to an issue concerning the entire system of scientific publishing: the verification of experimental images, often central to molecular biology papers, does not always manage to detect manipulations that remain unproven for years, even when the article in question is widely cited and discussed by the community. The retraction does not automatically amount to a definitive judgment on the hypothesis of beta-amyloid as a factor in Alzheimer’s, a field of study that has produced over the years further lines of research independent of that specific article; it does, however, amount to the formal removal of one of the most cited references in support of that mechanism.

It should be noted that the news currently comes from a single source (Il Giornale d’Italia, which reports the decision of Nature’s editorial team); no independent confirmation of the matter from another journalistic or institutional source is available in the material gathered. The retraction notice nonetheless remains an act of the journal itself, and is therefore a primary source regarding the fact it reports.

The case comes at a time when Alzheimer’s research is being pursued along multiple therapeutic and diagnostic lines, some of which do not depend on the now-retracted article. It remains to be seen what weight the scientific community will retroactively assign to the works that cited the 2006 study as a reference, and whether other journals will proceed with similar reviews of derivative materials.